Benefits Sleep regulation studied for promoting deeper, more restorative sleep phases Stress response linked to modulation of stress-related neuroendocrine activity Circadian rhythm balance explored for normalizing disrupted sleepwake cycles Recovery support interest in improved resilience and recovery in fatigue models Neuromodulation early research suggests possible interactions with opioid and NMDA pathways Localized Effects with Nasal Spray Rapid uptake through the nasal mucosa Direct modulation of sleep-related neuropeptide and stress-response pathways Formulated with a specialized isotonic nasal vehicle to minimize irritation and dryness What Researchers Use It For Regulation of sleep architecture, delta-wave activity, and circadian rhythms Interaction with corticotropin and stress hormone pathways Modulation of opioid peptide activity and pain-related signaling Potential antioxidant and neuroprotective roles in preclinical models Identity & Specs Sequence: Trp-Ala-Gly-Gly-Asp-Ala-Ser-Gly-Glu Formula / M.W.: C35H48N10O15, ~848.8 g/mol CAS: 62568-57-4 Form: Sterile nasal spray solution Net per vial: 10 mL (~100 sprays) Total Content: 5 mg DSIP per vial Purity: 99% (HPLC) Identity: MS-verified (per COA) Storage: 28 C, protect from light Selected Research PubChem entry chemical identity & registry: Original discovery (1977) isolation and initial findings: Sleep studies review DSIP in sleep regulation: Neuroendocrine effects corticotropin and stress hormone pathways: Disclaimer This product is intended for laboratory research use only

The longest follow-up spans 6 to 12 months in a retrospective case series with methodological limitations
Bradford assays Bradford assay was either purchased from Pierce or made in-house as described by Bradford 1972 [27]
Real humans, real fast Text us
Stress might cause psychological and physiological changes involving the activation of the hypothalamicpituitary-adrenal axis (HPA) and the sympathetic nervous system, which may influence the patient mood, behavior, and health [9]
Loss of p53 and SMAD4 induces adenosquamous subtype pancreatic cancer in the absence of an oncogenic KRAS mutation